Top Page
OKYO Pharma Limited Sponsored ADR
(NASDAQ:OKYO)
OKYO Pharma Limited Sponsored ADR (OKYO) vs. SPDR S&P 500 ETF (SPY)
OKYO Pharma Limited Sponsored ADR Business Overview & Revenue Model
OKYO Pharma Limited Sponsored ADR Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -2.56K | -2.56K | -3.87K | -3.80K | -2.42K | -13.09K |
| EBITDA | -7.08M | -7.08M | -15.75M | -13.18M | -6.21M | -3.35M |
| Net Income | -4.71M | -4.71M | -16.83M | -13.27M | -5.43M | -3.35M |
Balance Sheet | ||||||
| Total Assets | 3.68M | 3.68M | 1.54M | 5.20M | 4.30M | 7.09M |
| Cash, Cash Equivalents and Short-Term Investments | 1.56M | 1.56M | 826.85K | 4.05M | 2.70M | 6.89M |
| Total Debt | 0.00 | 0.00 | 0.00 | 2.22M | 0.00 | 98.76K |
| Total Liabilities | 9.23M | 9.23M | 7.42M | 7.26M | 1.35M | 1.77M |
| Stockholders Equity | -5.55M | -5.55M | -5.88M | -2.05M | 2.95M | 5.32M |
Cash Flow | ||||||
| Free Cash Flow | -1.81M | -1.81M | -9.49M | -7.70M | -5.47M | -1.61M |
| Operating Cash Flow | -1.81M | -1.81M | -9.49M | -7.70M | -5.47M | -1.60M |
| Investing Cash Flow | -1.21K | -1.21K | 0.00 | -5.92K | -1.67K | -18.11K |
| Financing Cash Flow | 2.10M | 2.66M | 6.21M | 9.32M | 2.15M | 7.83M |
OKYO Pharma Limited Sponsored ADR Technical Analysis
OKYO Pharma Limited Sponsored ADR Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $343.32M | -7.43 | -47.85% | ― | ― | -19.69% | |
52 Neutral | $84.62M | -17.05 | ― | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $120.54M | -0.84 | -85.93% | ― | ― | -60.99% | |
48 Neutral | $66.96M | -1.05 | -76.44% | ― | -10.03% | 11.06% | |
45 Neutral | $94.04M | -0.56 | -209.00% | ― | ― | 40.22% |
OKYO Pharma Limited Sponsored ADR Corporate Events
On January 5, 2026, OKYO Pharma appointed ophthalmology industry veteran Robert J. Dempsey as Chief Executive Officer and an executive board member, while former CEO Gary S. Jacob, Ph.D., moved into the role of Chief Development Officer and remained on the board. The board-approved leadership transition, effective immediately, is designed to maintain strategic continuity while sharpening OKYO’s commercial and development focus as it advances its flagship drug urcosimod for neuropathic corneal pain and other ocular inflammatory disorders; Dempsey’s track record in launching and commercializing blockbuster eye therapies such as Xiidra and Restasis is expected to strengthen OKYO’s positioning in the ophthalmology market and support the company’s next phase of growth around its planned larger Phase 2 NCP program.
The most recent analyst rating on (OKYO) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on OKYO Pharma Limited Sponsored ADR stock, see the OKYO Stock Forecast page.
On December 19, 2025, OKYO Pharma marked its progress in developing treatments for neuropathic corneal pain by having Executive Chairman and Founder Gabriele Cerrone and the management team ring the Opening Bell at the Nasdaq MarketSite in Times Square, New York. The ceremony highlighted the company’s clinical advances with its lead candidate urcosimod, which recently delivered positive Phase 2 results in NCP, demonstrating favorable corneal nerve outcomes and pain reduction in patients facing a debilitating condition without approved therapies. OKYO is leveraging this momentum as it prepares a larger, multicenter Phase 2 trial of urcosimod in NCP, planned to begin in the first quarter of 2026, underscoring its bid to strengthen its position in ocular pain therapeutics and signaling potential long-term implications for patients and investors if subsequent trials confirm these early efficacy signals.
The most recent analyst rating on (OKYO) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on OKYO Pharma Limited Sponsored ADR stock, see the OKYO Stock Forecast page.
On December 15, 2025, OKYO Pharma Limited announced that Panetta Partners Limited, associated with Executive Chairman Gabriele Cerrone, acquired 24,551 of the company’s ordinary shares on NASDAQ, increasing Cerrone’s total holding to 10,516,297 shares. This acquisition highlights the confidence in OKYO’s ongoing development of urcosimod, a promising treatment for neuropathic corneal pain and dry eye disease, which has shown significant results in Phase 2 trials, potentially enhancing the company’s market position in ophthalmology.
The most recent analyst rating on (OKYO) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on OKYO Pharma Limited Sponsored ADR stock, see the OKYO Stock Forecast page.
On December 11, 2025, OKYO Pharma Limited announced new analyses from a Phase 2 clinical trial of urcosimod, showing positive results in treating neuropathic corneal pain (NCP). The trial demonstrated that patients treated with 0.05% urcosimod experienced not only a reduction in pain but also favorable changes in corneal nerve structure, unlike the placebo group. These findings suggest urcosimod’s potential as a first-in-class therapeutic approach for NCP, highlighting its promise in restoring corneal nerve health and supporting further development.
The most recent analyst rating on (OKYO) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on OKYO Pharma Limited Sponsored ADR stock, see the OKYO Stock Forecast page.
On December 3, 2025, OKYO Pharma Limited announced that Panetta Partners Limited, associated with Executive Chairman Gabriele Cerrone, acquired 27,051 of the company’s ordinary shares on NASDAQ, increasing his total holdings to 10,491,746 shares. This acquisition underscores confidence in OKYO’s strategic direction, particularly as it advances urcosimod, which recently completed a Phase 2 trial for neuropathic corneal pain, potentially strengthening its market position in the ophthalmology sector.
The most recent analyst rating on (OKYO) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on OKYO Pharma Limited Sponsored ADR stock, see the OKYO Stock Forecast page.
On November 21, 2025, OKYO Pharma Limited announced that Panetta Partners Limited, associated with Executive Chairman Gabriele Cerrone, acquired 82,018 ordinary shares of the company on NASDAQ, increasing his total holding to 10,464,695 shares. This acquisition signifies a strong vote of confidence from the leadership in the company’s future prospects, particularly as OKYO has recently completed a Phase 2 trial of urcosimod for treating neuropathic corneal pain, a condition lacking FDA-approved therapies.
The most recent analyst rating on (OKYO) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on OKYO Pharma Limited Sponsored ADR stock, see the OKYO Stock Forecast page.
On November 18, 2025, OKYO Pharma Limited announced that its CEO, Gary S. Jacob, will present at the Ophthalmology Innovation Summit (OIS) XV in San Diego, scheduled for November 22, 2025. The presentation will focus on urcosimod, OKYO’s lead investigational drug for treating neuropathic corneal pain (NCP), a condition with no FDA-approved therapies. The announcement highlights OKYO’s recent positive Phase 2 trial results and its plans for a larger clinical trial, underscoring the company’s commitment to addressing unmet medical needs in the ophthalmic field.
The most recent analyst rating on (OKYO) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on OKYO Pharma Limited Sponsored ADR stock, see the OKYO Stock Forecast page.
On October 29, 2025, OKYO Pharma announced that its CEO, Dr. Gary S. Jacob, will present at the 33rd Annual BIO-Europe partnering conference in Vienna, Austria, scheduled for November 3-5, 2025. The presentation will highlight OKYO’s lead investigational candidate, urcosimod, and provide updates on its recently completed Phase 2 clinical trial for neuropathic corneal pain. This event represents a significant opportunity for OKYO to engage with global leaders and potential collaborators, potentially enhancing its industry positioning and accelerating the clinical development of urcosimod.
The most recent analyst rating on (OKYO) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on OKYO Pharma Limited Sponsored ADR stock, see the OKYO Stock Forecast page.
On October 16, 2025, OKYO Pharma Limited announced that Panetta Partners Limited, in which Executive Chairman Gabriele Cerrone has a beneficial interest, acquired 210,000 of the company’s ordinary shares on NASDAQ, increasing his total holding to 10,382,677 shares. This acquisition underscores confidence in the company’s strategic direction and its ongoing development of urcosimod, which has shown promising results in Phase 2 trials for treating neuropathic corneal pain and dry eye disease.
The most recent analyst rating on (OKYO) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on OKYO Pharma Limited Sponsored ADR stock, see the OKYO Stock Forecast page.